← Back to Search

Enzyme Inhibitor

Wee1 Inhibitor ZN-c3 for Fallopian Tube Cancer

Phase < 1
Waitlist Available
Led By Evthokia Hobbs, M.D.
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to 30 days after last dose of study intervention
Awards & highlights

Study Summary

This trial is testing a new drug, ZN-c3, to see if it is safe and has any side effects in treating patients with triple-negative breast cancer or ovarian cancer. ZN-c3 is a drug that may stop the growth of cancer cells.

Eligible Conditions
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Carcinoma
  • Peritoneal Cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to 30 days after last dose of study intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to 30 days after last dose of study intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells
Secondary outcome measures
CBR for ovarian cancer
Clinical benefit rate (CBR)
Overall survival
+2 more
Other outcome measures
Cellular and molecular characteristics
ZN-c3 tumor and plasma concentrations

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (wee1 inhibitor ZN-c3)Experimental Treatment1 Intervention
Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER
973 Previous Clinical Trials
7,385,812 Total Patients Enrolled
OHSU Knight Cancer InstituteLead Sponsor
230 Previous Clinical Trials
2,090,726 Total Patients Enrolled
Evthokia Hobbs, M.D.Principal InvestigatorOHSU Knight Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participants in this research trial?

"Reports on clinicaltrials.gov suggest that this study is not admitting new participants at the present moment, as it was last updated in September 2022. However, there are currently 4995 other medical trials actively recruiting patients right now."

Answered by AI

What objectives are being sought through this research endeavor?

"This trial will analyse the reduction in phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 within tumor cells during a 30 day period. Secondary objectives consist of evaluating complete response rates for ovarian cancer patients using Gynecological Cancer Intergroup (GCIG) criteria; time to disease progression from date of study treatment start until documented progression occurs; as well as measuring participants' progression free survival rate between cycle 1 day 1 dose administration and subsequent documentation of disease advancement or death."

Answered by AI

Who else is applying?

What state do they live in?
Oregon
How old are they?
65+
What site did they apply to?
OHSU Knight Cancer Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
Evthokia Hobbs 2023. "ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05368506.
~0 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top